Sera Prognostics Inc Class A SERA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026
-
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
-
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
-
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
-
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
Trading Information
- Previous Close Price
- $2.03
- Day Range
- $2.03–2.05
- 52-Week Range
- $1.56–3.95
- Bid/Ask
- $1.98 / $2.04
- Shares Outstanding
- 39.45M
- Market Cap
- $80.08M
- Volume/Avg
- 24,224 / 25,062
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,458.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 72
- Website
- https://www.seraprognostics.com
Valuation
|
Metric
|
SERA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.35 |
Price/Sales | 1,458.51 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SERA
|
|---|---|
Quick Ratio | 1.91 |
Current Ratio | 1.98 |
Interest Coverage | −5,303.00 |
Quick Ratio
SERA
Profitability
|
Metric
|
SERA
|
|---|---|
Return on Assets (Normalized) | −29.18% |
Return on Equity (Normalized) | −39.30% |
Return on Invested Capital (Normalized) | −43.28% |
Return on Assets
SERA
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|D>rWM< | LOCK|?>SFK | $174B | |||
| Medtronic PLC
MDT
| LOCK|N%Vny#J | LOCK|dC$@! | $119B | |||
| Stryker Corp
SYK
| LOCK|CV^#Lvg | LOCK|<^ | $114B | |||
| Boston Scientific Corp
BSX
| LOCK|p@@B@J | LOCK|#>$g> | $65B | |||
| Edwards Lifesciences Corp
EW
| LOCK|<X>!%lP# | LOCK|s@@r& | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|Pfm&QvG | LOCK|<^ | $31B | |||
| DexCom Inc
DXCM
| LOCK|pcvpjX$ | LOCK|hw%%# | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|nD! | LOCK|^F | $25B | |||
| Steris PLC
STE
| LOCK|>W%&<%k | LOCK|!xV$W | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|Hr^j>?x | LOCK|S%v | $18B |
United States